AR132249A1 - Formas microcristalinas de (r)-2-(n-[4-amino-5-(4-metoxibenzoil)tiazol-2-il]-4-fluoro-anilino)propanamida y procesos para su preparación - Google Patents

Formas microcristalinas de (r)-2-(n-[4-amino-5-(4-metoxibenzoil)tiazol-2-il]-4-fluoro-anilino)propanamida y procesos para su preparación

Info

Publication number
AR132249A1
AR132249A1 ARP240100756A ARP240100756A AR132249A1 AR 132249 A1 AR132249 A1 AR 132249A1 AR P240100756 A ARP240100756 A AR P240100756A AR P240100756 A ARP240100756 A AR P240100756A AR 132249 A1 AR132249 A1 AR 132249A1
Authority
AR
Argentina
Prior art keywords
methoxybenzoyl
propanamide
anilino
fluoro
amino
Prior art date
Application number
ARP240100756A
Other languages
English (en)
Spanish (es)
Inventor
Michal Sowa
Lucas Schreyer
Adrian Dobrowolski
Christoph Nboldt
Giovanni Maria Maggioni
Eva Lemann
Kersten Matthias Gericke
Maximilian Franz Ludwig Karl
Marko Ukrainczyk
Eoghan Delany
Jacek Zeglinski
Gary Morris
Brendan Roche
Richard Malpass-Evans
Ulrike Rhn
Original Assignee
Bayer Ag
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Deutsches Krebsforsch filed Critical Bayer Ag
Publication of AR132249A1 publication Critical patent/AR132249A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP240100756A 2023-03-31 2024-03-27 Formas microcristalinas de (r)-2-(n-[4-amino-5-(4-metoxibenzoil)tiazol-2-il]-4-fluoro-anilino)propanamida y procesos para su preparación AR132249A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23165818 2023-03-31

Publications (1)

Publication Number Publication Date
AR132249A1 true AR132249A1 (es) 2025-06-11

Family

ID=85795505

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100756A AR132249A1 (es) 2023-03-31 2024-03-27 Formas microcristalinas de (r)-2-(n-[4-amino-5-(4-metoxibenzoil)tiazol-2-il]-4-fluoro-anilino)propanamida y procesos para su preparación

Country Status (6)

Country Link
EP (1) EP4688760A1 (fr)
JP (1) JP2026511647A (fr)
CN (1) CN120957975A (fr)
AR (1) AR132249A1 (fr)
TW (1) TW202506653A (fr)
WO (1) WO2024200410A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025167814A1 (fr) * 2024-02-06 2025-08-14 微境生物医药科技(上海)有限公司 COMPOSÉ UTILISÉ EN TANT QU'INHIBITEUR DE DGKζ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115697980B (zh) 2020-04-24 2025-03-21 拜耳公司 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
US12350373B2 (en) 2021-09-24 2025-07-08 Bayer Aktiengesellschaft Nano-seeding

Also Published As

Publication number Publication date
WO2024200410A1 (fr) 2024-10-03
EP4688760A1 (fr) 2026-02-11
JP2026511647A (ja) 2026-04-14
CN120957975A (zh) 2025-11-14
TW202506653A (zh) 2025-02-16

Similar Documents

Publication Publication Date Title
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
MX2022015106A (es) Proceso para preparar tapinarof.
ECSP20048382A (es) Formas cristalinas novedosas
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
HUE050369T2 (hu) N - ((1,2,3,5,6,7-hexahidro-S-indacen-4-il) -karbamoil)-1-izopropil-1H-pirazol-3-szulfonamid nátrium-sója
BR112022002496A2 (pt) Compostos deuterados para uso no tratamento de câncer
AR132249A1 (es) Formas microcristalinas de (r)-2-(n-[4-amino-5-(4-metoxibenzoil)tiazol-2-il]-4-fluoro-anilino)propanamida y procesos para su preparación
CO2021017435A2 (es) Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
CO2023000039A2 (es) Formas en estado sólido de ciantraniliprol
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
CL2022000492A1 (es) Proceso para la preparación de estetrol de alta pureza.
EP3830456A4 (fr) Joint d'étanchéité de robinet à bille
BR112020026507A8 (pt) Composto de isotiazolo[5,4-d]pirimidinas como inibidor de irak4
BR112022016359A2 (pt) Formas cristalinas de um composto farmacêutico
EP4149420C0 (fr) Formulation de protéases pour le traitement d'infections microbiennes
BR112019002132A2 (pt) composições anti-retrovirais
EP4029509A4 (fr) Composition pour augmenter l'effet d'un médicament de type anticorps
BR112022002459A2 (pt) Processo para a preparação de 2-cloro-1-(2-clorotiazol-5-il)etanona
MX2021010945A (es) Formula que enmascara el sabor para compuestos de cuerpos cetonicos.
CA3287003A1 (fr) Formes microcristallines de (r)-2-(n-[4-amino-5-(4-méthoxybenzoyl)thiazol-2-yl]-4-fluoroanilino)propanamide et leurs procédés de préparation
IT201900020418A1 (it) Composizione e formulazione per il trattamento di gas e gonfiore intestinale
EP4413997A4 (fr) Formulation de médicament d'anticorps anti-hla-dq2.5
IL314815A (en) Processes and compounds for preparing spiroligomers
MX2018009558A (es) Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.
GT200600141A (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares

Legal Events

Date Code Title Description
FB Suspension of granting procedure